Belgium· BE-AMP-SAM490435-00
Emend 125 mg
A aprepitant product containing aprepitant, registered in Belgium by Merck Sharp & Dohme. The same ATC class is registered in 17 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Aprepitant is registered in 17 of 19 countries.
Countries holding a registration under ATC A04AD12 (aprepitant), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Aprepitant · ATC A04AD12
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of aprepitant costs, country by country.
Normalised to the WHO defined daily dose (165 mg), the median price runs from $0.40 in Finland to $157.48 in United States — a ×394 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Aprepitant · price per daily dose (165 mg)
USD · FX 28 Sept 2026
- US United States$157.48 (acquisition cost)
- CH Switzerland$73.26
- FR France$33.15
- FI Finland$0.40
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Aprepitant
- Manufacturer
- Merck Sharp & Dohme
- Country
- Belgium (BE)
- ATC code
- A04AD12
- ATC class
- Aprepitant
- Defined daily dose
- 165 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb7723653
- be_apb3621158
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
583 interactions on record for aprepitant.
Graded by severity as the source publishes them — 73 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aprepitant · interactions on record
583 records
- 73 severe
- 380 moderate
- 25 minor
- 104 info
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- LonafarnibA16AX20severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aprepitant in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEMENDMerck Sharp & Dohme B.V., Haarlem
- SpainEMEND 125 MG POLVO PARA SUSPENSION ORALMerck Sharp & Dohme B.V.
- FinlandEmendMerck Sharp & Dohme B.V.
- FranceEMEND 125 mg, poudre pour suspension buvableMERCK SHARP & DOHME (PAYS-BAS)
- United KingdomEmend 125mg oral powder sachetsMerck Sharp & Dohme (UK) Ltd
- IrelandEmend 125 mg powder for oral suspensionMerck Sharp & Dohme BV,
- IcelandEmendMerck Sharp & Dohme B.V.*
- NetherlandsEmend 125 mg, poeder voor orale suspensieMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 26 EEA countries. Names it is sold under:
- Austria · Aprepitant Accord, Aprepitant Ratiopharm
- Cyprus · Atanto, Endrem
- Czechia · Aprepitant Accord, Aprepitant Sandoz
- Germany · Aprepilor, Aprepitant Al
- Denmark · Aprepitant "medical Valley", Aprepitant Medical Valley
- Estonia · Aprepitant Sandoz
- Spain · Aprepitant Accord, Aprepitant Qilu
- Finland · Aprepitant Stada
- France · Aprepitant Accord, Aprepitant Aprepitant
- United Kingdom (Northern Ireland) · Aprepitant, Aprepitant Accord
- Greece · Aprepitant Win Medica, Atanto
- Croatia · Aprepitant Alpha-Medical, Aprepitant Sandoz
- Hungary · Aprepitant Pharmacenter, Aprepitant Q Pharma
- Ireland · Aprepitant Accord
- Iceland · Aprepitant Medical Valley, Aprepitant Stada
- Italy · Aprepitant Accord, Aprepitant Teva
- Liechtenstein · Emend
- Lithuania · Aprepitant Sandoz
- Latvia · Aprepitant Sandoz
- Netherlands · Aprepitant Accord, Aprepitant Aurobind
- Norway · Emend
- Poland · Aprepitant Accord, Aprepitant Sandoz
- Portugal · Aprepitant Generis
- Sweden · Aprepitant Medical Valley, Aprepitant Stada
- Slovenia · Aprepitant Teva
- Slovakia · Aprepitant, Aprepitant Stada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/15e24e61-7eee-443d-a851-636160fc183f GET /v1/drugs/15e24e61-7eee-443d-a851-636160fc183f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for oral suspension",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Emend 125 mg",
"name_fr": "Emend 125 mg",
"name_nl": "Emend 125 mg",
"amp_code": "SAM490435-00",
"strengths": [
"125.0000",
"468.7000",
"125.0000"
],
"pack_count": 1,
"substances": [
"Aprepitant",
"Lactose",
"Sodium Laurilsulfate",
"Sodium Stearyl Fumarate",
"Sucrose"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Aprepitant",
"authorisation_numbers": [
"EU/1/03/262/011"
]
}See everything about aprepitant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.